TGTX
TG Therapeutics (TGTX)
$40
About TG Therapeutics (TGTX)
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$57.38
52 Week Low
$25.28
Market cap
8.3B
Dividend yield
0.00%
Volume
12,621
Avg. volume
2.6M
P/E ratio
18.96
TG Therapeutics News
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$57.38
52 Week Low
$25.28
Market cap
8.3B
Dividend yield
0.00%
Volume
12,621
Avg. volume
2.6M
P/E ratio
18.96